The Technical Analyst
Select Language :
C4 Therapeutics, Inc. [CCCC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

C4 Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

C4 Therapeutics, Inc. is listed at the  Exchange

1.49% $8.17

America/New_York / 28 mar 2024 @ 16:00


C4 Therapeutics, Inc.: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 560.47 mill
EPS: -2.67
P/E: -3.06
Earnings Date: May 02, 2024
SharesOutstanding: 68.60 mill
Avg Daily Volume: 4.43 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Neutral
DE: Buy
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -3.06 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.52x
Company: PE -3.06 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-1.148
(-114.05%) $-9.32
Date: 2024-03-29
Expected Trading Range (DAY)

$ 7.33 - 9.01

( +/- 10.28%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-07 Boyle Scott N Buy 115 000 Stock Option (Right to Buy)
2024-03-07 Boyle Scott N Sell 115 000 Stock Option (Right to Buy)
2024-03-07 Fisher Stewart Buy 118 000 Stock Option (Right to Buy)
2024-03-07 Fisher Stewart Buy 94 950 Stock Option (Right to Buy)
2024-03-07 Fisher Stewart Sell 118 000 Stock Option (Right to Buy)
INSIDER POWER
60.56
Last 98 transactions
Buy: 4 666 481 | Sell: 1 001 966

Forecast: 16:00 - $8.17

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $8.17
Forecast 2: 16:00 - $8.17
Forecast 3: 16:00 - $8.17
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $8.17 (1.49% )
Volume 1.866 mill
Avg. Vol. 4.43 mill
% of Avg. Vol 42.15 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for C4 Therapeutics, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for C4 Therapeutics, Inc.

RSI

Intraday RSI14 chart for C4 Therapeutics, Inc.

Last 10 Buy & Sell Signals For CCCC

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$5.63N/AActive
Profile picture for
            C4 Therapeutics, Inc.

CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Last 10 Buy Signals

Date Signal @
OMUSDMar 29 - 05:190.710
KUBUSDMar 29 - 05:132.70
EOSUSDMar 29 - 05:15$1.083
HATUSDMar 29 - 05:023 532.25
FETUSDMar 29 - 04:58$3.24
SOCKSUSDMar 29 - 04:5335 606
OSHIUSDMar 29 - 04:4981.91
HBTCUSDMar 29 - 04:3834 558
DESOUSDMar 29 - 04:3931.41
ARUSDMar 29 - 04:28$41.19

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.